November 20, 2026

Pfizer moves forward with once-daily weight loss pill

The drugmaker last year scrapped a separate, once-a-day pill due to concerns about liver safety

Pfizer moves forward with once-daily weight loss pill
A person walks past the Pfizer Headquarters building in the Manhattan borough of New York City, New York, U.S., December 7, 2020. REUTERS/Carlo Allegri/File Photo

bdnews24.com

Reuters

Published : 11 Jul 2024, 11:34 PM

Updated : 21 Aug 2026, 11:40 AM

Pfizer  said on Thursday it would advance a reworked, once-a-day version of its experimental obesity pill, danuglipron to clinical trials in the second half of this year, sending its shares 5 percent higher in premarket trading.

The drugmaker last year said it was focusing on danuglipron's development after scrapping a separate, once-daily pill due to concerns about liver safety.

Pfizer was testing both a once-daily modified release dosing and also a twice-daily form of danuglipron.

It said early study results supported a once-daily dosing, with a safety profile consistent with prior danuglipron twice-daily dosage studies, including no liver enzyme elevations observed in more than 1,400 healthy adult volunteers.

The Pfizer drug is part of the second-generation of weight loss pills, under development by companies including Eli Lilly and Novo Nordisk that will offer patients more convenient dosing instead of injections.

Related Stories